Tizanidine - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (4)Enzymes (1)

Targets (4)Enzymes (1)Biointeractions (5)

Identification

Name

Tizanidine

Accession Number

DB00697 (APRD00128)

Type

Small Molecule

Groups

Approved

Description

Tizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole

Tizanidin

Tizanidina

Tizanidine

Tizanidinum

External IDs

AN 021 / DS 103-282

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Tizanidine Hydrochloride	B53E3NMY5C	64461-82-1	ZWUKMNZJRDGCTQ-UHFFFAOYSA-N	Details

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Mylan-tizanidine	Tablet	4 mg	Oral	Mylan Pharmaceuticals	2006-02-16	2017-01-09	Canada
Pal-tizanidine	Tablet	4 mg	Oral	Paladin Labs Inc	1999-10-29	Not applicable	Canada
Tizanidine	Tablet	2 mg	Oral	Aa Pharma Inc	Not applicable	Not applicable	Canada
Tizanidine	Tablet	4 mg	Oral	Aa Pharma Inc	2004-11-17	Not applicable	Canada
Tizanidine Hydrochloride	Capsule, gelatin coated	6 mg/1	Oral	Actavis Pharma Company	2012-02-06	Not applicable	US
Tizanidine Hydrochloride	Capsule, gelatin coated	2 mg/1	Oral	Clinical Solutions Wholsesale	2012-02-06	Not applicable	US
Tizanidine Hydrochloride	Capsule, gelatin coated	6 mg/1	Oral	bryant ranch prepack	2012-02-06	Not applicable	US
Tizanidine Hydrochloride	Capsule, gelatin coated	2 mg/1	Oral	Actavis Pharma Company	2012-02-06	Not applicable	US
Tizanidine Hydrochloride	Capsule, gelatin coated	4 mg/1	Oral	Actavis Pharma Company	2012-02-06	Not applicable	US
Zanaflex	Capsule	4 mg/1	Oral	Stat Rx USA	2002-08-29	Not applicable	US
Zanaflex	Tablet	4 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1997-01-01	Not applicable	US
Zanaflex	Tablet	4 mg/1	Oral	Acorda Therapeutics	1997-01-01	Not applicable	US
Zanaflex	Capsule, gelatin coated	4 mg/1	Oral	Rebel Distributors	2002-08-29	Not applicable	US
Zanaflex	Capsule	2 mg/1	Oral	Acorda Therapeutics	2005-04-04	Not applicable	US
Zanaflex	Capsule	2 mg/1	Oral	Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc	2012-03-28	Not applicable	US
Zanaflex	Capsule	4 mg/1	Oral	Acorda Therapeutics	2005-04-04	Not applicable	US
Zanaflex	Capsule	4 mg/1	Oral	Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc	2012-03-28	Not applicable	US
Zanaflex	Capsule	6 mg/1	Oral	Acorda Therapeutics	2005-04-04	Not applicable	US
Zanaflex	Capsule	6 mg/1	Oral	Stat Rx USA	2002-08-29	Not applicable	US
Zanaflex	Capsule	6 mg/1	Oral	Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc	2012-03-28	Not applicable	US

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Comfort Pac With Tizanidine	Kit			Pd Rx Pharmaceuticals, Inc.	2013-07-09	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2003-05-06	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Remedy Repack	2015-09-02	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	St. Marys Medical Park Pharmacy	2015-08-18	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	bryant ranch prepack	2002-07-03	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	A S Medication Solutions	2004-01-16	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2002-07-03	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Remedy Repack	2013-05-23	2017-01-06	US
Tizanidine	Tablet	4 mg/1	Oral	Cardinal Health	2011-01-28	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	bryant ranch prepack	2003-12-11	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Amerincan Health Packaging	2013-09-25	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-03-16	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Aidarex Pharmaceuticals LLC	2002-07-03	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Mylan Pharmaceuticals	2003-05-06	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Blenheim Pharmacal, Inc.	2014-04-08	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2002-07-03	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Remedy Repack	2017-01-17	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Unichem Pharmaceuticals (USA), Inc.	2013-04-01	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2014-03-05	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2003-05-06	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Unit Dose Services	2002-07-03	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	New Horizon Rx Group, LLC	2013-08-25	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Remedy Repack	2015-12-15	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Directrx	2014-01-01	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	A S Medication Solutions	2002-07-03	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	A S Medication Solutions	2013-04-01	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	H.J. Harkins Company	2002-07-03	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Cardinal Health	2013-03-21	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	bryant ranch prepack	2002-07-03	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Amerincan Health Packaging	2014-06-02	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2002-07-03	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Blenheim Pharmacal, Inc.	2014-12-18	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Aidarex Pharmaceuticals LLC	2003-12-11	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Proficient Rx LP	2003-12-11	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Mesource Pharmaceuticals	2008-12-08	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Unit Dose Services	2002-07-03	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Golden State Medical Supply	2004-01-16	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2013-04-01	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Directrx	2014-01-01	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2013-04-01	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	A S Medication Solutions	2004-01-16	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	H.J. Harkins Company	2002-07-03	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Sun Pharmaceutical Industries Limited	2003-12-11	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Altura Pharmaceuticals, Inc.	2010-01-01	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Av Kare, Inc.	2015-07-23	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2002-07-03	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Stat Rx USA	2002-07-03	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	bryant ranch prepack	2004-01-16	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Mesource Pharmaceuticals	2009-01-05	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Mylan Institutional	2003-06-15	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Golden State Medical Supply	2004-01-16	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Dr Reddy's Laboratories	2002-07-03	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Proficient Rx LP	2002-07-03	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2004-01-16	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Physicians Total Care, Inc.	2004-01-19	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Sun Pharmaceutical Industries Limited	2003-12-11	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Core Pharma, Llc	2007-02-06	2016-10-13	US
Tizanidine	Tablet	4 mg/1	Oral	Av Kare, Inc.	2015-07-23	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Stat Rx USA	2002-07-03	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	A S Medication Solutions	2003-12-11	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Remedy Repack	2014-11-21	2017-04-19	US
Tizanidine	Tablet	4 mg/1	Oral	Remedy Repack	2013-02-19	2017-01-18	US
Tizanidine	Tablet	4 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2004-01-16	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Apotex Corporation	2004-01-16	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Dr Reddy's Laboratories	2002-07-03	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Proficient Rx LP	2004-01-16	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	A S Medication Solutions	2002-07-03	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-08-01	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Physicians Total Care, Inc.	2004-03-03	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Clinical Solutions Wholsesale	2002-07-03	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Core Pharma, Llc	2007-02-06	2016-10-13	US
Tizanidine	Tablet	4 mg/1	Oral	Mc Kesson Contract Packaging	2012-02-23	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Blenheim Pharmacal, Inc.	2014-01-22	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Major	2014-10-01	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Remedy Repack	2013-05-15	2017-01-11	US
Tizanidine	Tablet	2 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2002-11-26	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Apotex Corporation	2004-01-16	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Proficient Rx LP	2013-04-01	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	A S Medication Solutions	2003-12-11	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2002-07-03	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Cardinal Health	2002-07-03	2016-03-22	US
Tizanidine	Tablet	4 mg/1	Oral	Dispensing Solutions, Inc.	2002-07-03	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Aidarex Pharmaceuticals LLC	2002-07-03	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Mylan Pharmaceuticals	2003-05-06	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Blenheim Pharmacal, Inc.	2014-01-13	Not applicable	US
Tizanidine	Tablet	4 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2013-04-01	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2003-12-11	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Unichem Pharmaceuticals (USA), Inc.	2013-04-01	Not applicable	US
Tizanidine	Tablet	2 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2014-03-26	Not applicable	US
Tizanidine HCl	Tablet	4 mg/1	Oral	Northwind Pharmaceuticals	2017-01-25	Not applicable	US
Tizanidine Hydrochloride	Tablet	2 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-04-20	2017-03-17	US
Tizanidine Hydrochloride	Capsule	4 mg/1	Oral	Zydus Pharmaceuticals Usa, Inc.	2017-04-27	Not applicable	US
Tizanidine Hydrochloride	Capsule, gelatin coated	6 mg/1	Oral	Av Kare, Inc.	2014-06-20	Not applicable	US
Tizanidine Hydrochloride	Capsule	6 mg/1	Oral	Zydus Pharmaceuticals Usa, Inc.	2017-04-27	Not applicable	US
Tizanidine Hydrochloride	Tablet	2 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2007-02-06	Not applicable	US
Tizanidine Hydrochloride	Tablet	2 mg/1	Oral	Stat Rx USA	2002-11-26	Not applicable	US
Tizanidine Hydrochloride	Tablet	4 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2002-06-27	Not applicable	US
Tizanidine Hydrochloride	Capsule	2 mg/1	Oral	Cadila Pharnmaceuticals	2017-04-27	Not applicable	US
Tizanidine Hydrochloride	Tablet	2 mg/1	Oral	Keltman Pharmaceuticals Inc.	2005-06-01	Not applicable	US
Tizanidine Hydrochloride	Tablet	4 mg/1	Oral	Stat Rx USA	2002-06-27	Not applicable	US
Tizanidine Hydrochloride	Tablet	2 mg/1	Oral	Eon Labs, Inc.	2002-11-26	Not applicable	US
Tizanidine Hydrochloride	Capsule	2 mg/1	Oral	Mylan Pharmaceuticals	2013-03-01	Not applicable	US
Tizanidine Hydrochloride	Capsule, gelatin coated	2 mg/1	Oral	Apotex Corporation	2012-02-06	Not applicable	US
Tizanidine Hydrochloride	Capsule	4 mg/1	Oral	Cadila Pharnmaceuticals	2017-04-27	Not applicable	US
Tizanidine Hydrochloride	Tablet	2 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-06-28	Not applicable	US
Tizanidine Hydrochloride	Tablet	4 mg/1	Oral	Keltman Pharmaceuticals Inc.	2005-06-01	Not applicable	US
Tizanidine Hydrochloride	Tablet	4 mg/1	Oral	Major	2010-07-16	Not applicable	US
Tizanidine Hydrochloride	Tablet	4 mg/1	Oral	Eon Labs, Inc.	2002-06-27	Not applicable	US
Tizanidine Hydrochloride	Capsule	4 mg/1	Oral	Mylan Pharmaceuticals	2013-03-01	Not applicable	US
Tizanidine Hydrochloride	Capsule, gelatin coated	4 mg/1	Oral	Apotex Corporation	2012-02-06	Not applicable	US
Tizanidine Hydrochloride	Capsule	6 mg/1	Oral	Cadila Pharnmaceuticals	2017-04-27	Not applicable	US
Tizanidine Hydrochloride	Tablet	4 mg/1	Oral	Rebel Distributors	2007-02-06	Not applicable	US
Tizanidine Hydrochloride	Capsule, gelatin coated	2 mg/1	Oral	Av Kare, Inc.	2014-06-20	Not applicable	US
Tizanidine Hydrochloride	Tablet	2 mg/1	Oral	Rebel Distributors	2007-02-06	Not applicable	US
Tizanidine Hydrochloride	Tablet	4 mg/1	Oral	TIZANIDINE HYDROCHLORIDE	2014-01-01	Not applicable	US
Tizanidine Hydrochloride	Capsule	6 mg/1	Oral	Mylan Pharmaceuticals	2013-03-01	Not applicable	US
Tizanidine Hydrochloride	Capsule, gelatin coated	6 mg/1	Oral	Apotex Corporation	2012-02-06	Not applicable	US
Tizanidine Hydrochloride	Tablet	4 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2010-11-23	Not applicable	US
Tizanidine Hydrochloride	Capsule	2 mg/1	Oral	Zydus Pharmaceuticals Usa, Inc.	2017-04-27	Not applicable	US
Tizanidine Hydrochloride	Tablet	4 mg/1	Oral	Clinical Solutions Wholsesale	2002-06-27	Not applicable	US
Tizanidine Hydrochloride	Tablet	4 mg/1	Oral	bryant ranch prepack	2002-06-27	Not applicable	US
Tizanidine Hydrochloride	Tablet	4 mg/1	Oral	Amerincan Health Packaging	2013-07-08	2015-12-29	US
Tizanidine Hydrochloride	Capsule, gelatin coated	4 mg/1	Oral	Av Kare, Inc.	2014-06-20	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Cimbrar	Euroetika
Musant	Actavis
Myores	Meprofarm
Navizan	Caber
Relaxkov	Blaskov
Sirdalid	Novartis
Sirdalud	Novartis
Sirdalud MR	Novartis
Sizolan	Dr. Reddy's
Spaslax	Panion & BF
Telzanine	Nisshin Seiyaku
Ternelin	Novartis
Tizadin	ACL
Tizaflex	Actavis
Tizalud	Opsonin
Tizan	Sun
Zanpeak	Tatsumi Kagaku
Zitanid	Novell

Brand mixtures

Not Available

Categories

UNII

6AI06C00GW

CAS number

51322-75-9

Weight

Average: 253.711
Monoisotopic: 253.018893678

Chemical Formula

C₉H₈ClN₅S

InChI Key

XFYDIVBRZNQMJC-UHFFFAOYSA-N

InChI

InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)

IUPAC Name

5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine

SMILES

ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1

Pharmacology

Indication

For the management of increased muscle tone associated with spasticity

Structured Indications

Pharmacodynamics

Mechanism of action

Tizanidine reduces spasticity by increasing presynaptic inhibition of motor neurons through agonist action at a2-adrenergic receptor sites.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Alpha-2A adrenergic receptor	Protein	unknown	agonist	Human	P08913	details
Alpha-2B adrenergic receptor	Protein	yes	agonist	Human	P18089	details
Alpha-2C adrenergic receptor	Protein	yes	agonist	Human	P18825	details
Nischarin	Protein	no	agonist	Human	Q9Y2I1	details

Absorption

Not Available

Volume of distribution

2.4 L/kg

Protein binding

30%

Metabolism

Substrate	Enzymes	Product
Tizanidine	Cytochrome P450 1A2	5-chloro-4-(guanidino)-2,1,3-benzothiadiazole	Details
Tizanidine	Cytochrome P450 1A2	5-chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiadiazole	Details

Route of elimination

Approximately 95% of an administered dose is metabolized.

Half life

2.5 hours

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
7-Nitroindazole	The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tizanidine.	Experimental
Abiraterone	The serum concentration of Tizanidine can be increased when it is combined with Abiraterone.	Approved
Acebutolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved
Acepromazine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Tizanidine.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Aceprometazine is combined with Tizanidine.	Approved
Acetazolamide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Acetazolamide.	Approved, Vet Approved
Aciclovir	The serum concentration of Tizanidine can be increased when it is combined with Aciclovir.	Approved
Adipiplon	The risk or severity of adverse effects can be increased when adipiplon is combined with Tizanidine.	Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Agomelatine is combined with Tizanidine.	Approved, Investigational
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tizanidine.	Approved
Alfaxalone	The risk or severity of adverse effects can be increased when Alfaxalone is combined with Tizanidine.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Alfentanil is combined with Tizanidine.	Approved, Illicit
Alfuzosin	Alfuzosin may decrease the vasoconstricting activities of Tizanidine.	Approved, Investigational
Aliskiren	The risk or severity of adverse effects can be increased when Tizanidine is combined with Aliskiren.	Approved, Investigational
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Tizanidine.	Experimental, Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Tizanidine.	Approved, Illicit, Investigational
Alprenolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.	Approved, Withdrawn
Amifostine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Amifostine.	Approved, Investigational
Amiloride	The risk or severity of adverse effects can be increased when Amiloride is combined with Tizanidine.	Approved
Amineptine	Amineptine may decrease the antihypertensive activities of Tizanidine.	Illicit, Withdrawn
Aminophylline	The serum concentration of Tizanidine can be increased when it is combined with Aminophylline.	Approved
Amiodarone	The serum concentration of Tizanidine can be increased when it is combined with Amiodarone.	Approved, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Amisulpride is combined with Tizanidine.	Approved, Investigational
Amitriptyline	The serum concentration of Tizanidine can be increased when it is combined with Amitriptyline.	Approved
Amlodipine	The serum concentration of Tizanidine can be increased when it is combined with Amlodipine.	Approved
Amobarbital	The risk or severity of adverse effects can be increased when Amobarbital is combined with Tizanidine.	Approved, Illicit
Amoxapine	The risk or severity of adverse effects can be increased when Amoxapine is combined with Tizanidine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Amperozide is combined with Tizanidine.	Experimental
Amphotericin B	The risk or severity of adverse effects can be increased when Tizanidine is combined with Amphotericin B.	Approved, Investigational
Amyl Nitrite	The risk or severity of adverse effects can be increased when Tizanidine is combined with Amyl Nitrite.	Approved
Anagrelide	Tizanidine may increase the QTc-prolonging activities of Anagrelide.	Approved
Anastrozole	The serum concentration of Tizanidine can be increased when it is combined with Anastrozole.	Approved, Investigational
Apomorphine	The serum concentration of Tizanidine can be increased when it is combined with Apomorphine.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Apraclonidine.	Approved
Aripiprazole	Aripiprazole may increase the hypotensive activities of Tizanidine.	Approved, Investigational
Arotinolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.	Approved
Arsenic trioxide	Tizanidine may increase the QTc-prolonging activities of Arsenic trioxide.	Approved, Investigational
Artemether	Tizanidine may increase the QTc-prolonging activities of Artemether.	Approved
Articaine	The risk or severity of adverse effects can be increased when Articaine is combined with Tizanidine.	Approved
Asenapine	Tizanidine may increase the QTc-prolonging activities of Asenapine.	Approved
Atazanavir	The serum concentration of Tizanidine can be increased when it is combined with Atazanavir.	Approved, Investigational
Atenolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Atenolol.	Approved
Azelastine	Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azelastine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Azelastine.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Tizanidine is combined with Azilsartan medoxomil.	Approved
Azithromycin	The serum concentration of Tizanidine can be increased when it is combined with Azithromycin.	Approved
Baclofen	The risk or severity of adverse effects can be increased when Baclofen is combined with Tizanidine.	Approved
Barbexaclone	Barbexaclone may increase the hypotensive activities of Tizanidine.	Experimental
Barbital	The risk or severity of adverse effects can be increased when Barbital is combined with Tizanidine.	Illicit
Barnidipine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Barnidipine.	Approved
Bedaquiline	Tizanidine may increase the QTc-prolonging activities of Bedaquiline.	Approved
Befunolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Befunolol.	Experimental
Benazepril	Tizanidine may increase the hypotensive activities of Benazepril.	Approved, Investigational
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Tizanidine.	Approved
Benzocaine	The risk or severity of adverse effects can be increased when Benzocaine is combined with Tizanidine.	Approved
Benzyl alcohol	The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tizanidine.	Approved
Benzylpenicilloyl Polylysine	Tizanidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.	Approved
Bepridil	The risk or severity of adverse effects can be increased when Tizanidine is combined with Bepridil.	Approved, Withdrawn
Beractant	Tizanidine may increase the bradycardic activities of Beractant.	Approved
Betaxolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Betaxolol.	Approved
Bevantolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.	Approved
Bisoprolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.	Approved
Bopindolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.	Approved
Bortezomib	The serum concentration of Tizanidine can be increased when it is combined with Bortezomib.	Approved, Investigational
Bretylium	Bretylium may increase the bradycardic activities of Tizanidine.	Approved
Brexpiprazole	The risk or severity of adverse effects can be increased when Tizanidine is combined with Brexpiprazole.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Brimonidine is combined with Tizanidine.	Approved
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved
Bromazepam	The risk or severity of adverse effects can be increased when Bromazepam is combined with Tizanidine.	Approved, Illicit
Bromocriptine	The serum concentration of Tizanidine can be increased when it is combined with Bromocriptine.	Approved, Investigational
Brompheniramine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Brompheniramine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Brotizolam is combined with Tizanidine.	Approved, Withdrawn
Bufuralol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.	Experimental, Investigational
Bumetanide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Bumetanide.	Approved
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Tizanidine.	Approved, Investigational
Bupranolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.	Approved
Buprenorphine	The serum concentration of Tizanidine can be increased when it is combined with Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The risk or severity of adverse effects can be increased when Buspirone is combined with Tizanidine.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Tizanidine.	Approved, Illicit
Butalbital	The risk or severity of adverse effects can be increased when Butalbital is combined with Tizanidine.	Approved, Illicit
Butethal	The risk or severity of adverse effects can be increased when Butethal is combined with Tizanidine.	Approved, Illicit
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Tizanidine.	Approved, Illicit, Vet Approved
Cabergoline	Cabergoline may increase the hypertensive activities of Tizanidine.	Approved
Caffeine	The serum concentration of Tizanidine can be increased when it is combined with Caffeine.	Approved
Calfactant	Tizanidine may increase the bradycardic activities of Calfactant.	Approved
Canagliflozin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Canagliflozin.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Tizanidine is combined with Candesartan.	Approved
Candoxatril	Tizanidine may increase the hypotensive activities of Candoxatril.	Experimental
Captopril	Tizanidine may increase the hypotensive activities of Captopril.	Approved
Carbamazepine	The metabolism of Tizanidine can be increased when combined with Carbamazepine.	Approved, Investigational
Carbetocin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Carbetocin.	Approved
Carbimazole	The serum concentration of Tizanidine can be increased when it is combined with Carbimazole.	Approved
Carbinoxamine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Carbinoxamine.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Carfentanil is combined with Tizanidine.	Illicit, Vet Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Carisoprodol is combined with Tizanidine.	Approved
Carteolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Carteolol.	Approved
Carvedilol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.	Approved, Investigational
Celiprolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Celiprolol.	Approved, Investigational
Ceritinib	Tizanidine may increase the bradycardic activities of Ceritinib.	Approved
Cetirizine	The risk or severity of adverse effects can be increased when Cetirizine is combined with Tizanidine.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tizanidine.	Approved, Illicit, Vet Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tizanidine.	Approved, Illicit
Chlormezanone	The risk or severity of adverse effects can be increased when Chlormezanone is combined with Tizanidine.	Approved, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tizanidine.	Approved
Chloroquine	Tizanidine may increase the QTc-prolonging activities of Chloroquine.	Approved, Vet Approved
Chlorothiazide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Chlorothiazide.	Approved, Vet Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Chlorphenamine.	Approved
Chlorpromazine	Tizanidine may increase the QTc-prolonging activities of Chlorpromazine.	Approved, Vet Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tizanidine.	Approved, Withdrawn
Chlorthalidone	The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Tizanidine.	Approved
Chlorzoxazone	The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tizanidine.	Approved
Cilazapril	Tizanidine may increase the hypotensive activities of Cilazapril.	Approved
Cilnidipine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Cilnidipine.	Approved
Cimetidine	The serum concentration of Tizanidine can be increased when it is combined with Cimetidine.	Approved
Cinchocaine	The risk or severity of adverse effects can be increased when Cinchocaine is combined with Tizanidine.	Approved, Vet Approved
Ciprofloxacin	Tizanidine may increase the QTc-prolonging activities of Ciprofloxacin.	Approved, Investigational
Cisapride	Tizanidine may increase the QTc-prolonging activities of Cisapride.	Approved, Investigational, Withdrawn
Citalopram	The serum concentration of Tizanidine can be increased when it is combined with Citalopram.	Approved
Clarithromycin	The serum concentration of Tizanidine can be increased when it is combined with Clarithromycin.	Approved
Clemastine	The risk or severity of adverse effects can be increased when Clemastine is combined with Tizanidine.	Approved
Clevidipine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Clevidipine.	Approved
Clidinium	The risk or severity of adverse effects can be increased when Tizanidine is combined with Clidinium.	Approved
Clobazam	The risk or severity of adverse effects can be increased when Clobazam is combined with Tizanidine.	Approved, Illicit
Clofarabine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Clofarabine.	Approved, Investigational
Clomipramine	Clomipramine may decrease the antihypertensive activities of Tizanidine.	Approved, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Clonazepam.	Approved, Illicit
Clonidine	The risk or severity of adverse effects can be increased when Clonidine is combined with Tizanidine.	Approved
Clorazepate	The risk or severity of adverse effects can be increased when Clorazepate is combined with Tizanidine.	Approved, Illicit
Clotrimazole	The serum concentration of Tizanidine can be increased when it is combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The serum concentration of Tizanidine can be increased when it is combined with Clozapine.	Approved
Cocaine	The risk or severity of adverse effects can be increased when Cocaine is combined with Tizanidine.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Tizanidine.	Approved, Illicit
Conivaptan	The risk or severity of adverse effects can be increased when Tizanidine is combined with Conivaptan.	Approved, Investigational
Conjugated Equine Estrogens	The serum concentration of Tizanidine can be increased when it is combined with Conjugated Equine Estrogens.	Approved
Crizotinib	Tizanidine may increase the QTc-prolonging activities of Crizotinib.	Approved
Cyclizine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Cyclizine.	Approved
Cyclobenzaprine	Cyclobenzaprine may decrease the antihypertensive activities of Tizanidine.	Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tizanidine.	Approved
Cyproterone acetate	The serum concentration of Tizanidine can be decreased when it is combined with Cyproterone acetate.	Approved, Investigational
Dantrolene	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dantrolene.	Approved
Dapagliflozin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dapagliflozin.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Dapiprazole is combined with Tizanidine.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dapoxetine.	Investigational
Deferasirox	The serum concentration of Tizanidine can be increased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The serum concentration of Tizanidine can be increased when it is combined with Delavirdine.	Approved
Deramciclane	The risk or severity of adverse effects can be increased when deramciclane is combined with Tizanidine.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Desflurane is combined with Tizanidine.	Approved
Desipramine	Desipramine may decrease the antihypertensive activities of Tizanidine.	Approved
Desloratadine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Desloratadine.	Approved, Investigational
Desvenlafaxine	Desvenlafaxine may increase the tachycardic activities of Tizanidine.	Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tizanidine.	Approved
Dexmedetomidine	The serum concentration of Tizanidine can be increased when it is combined with Dexmedetomidine.	Approved, Vet Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Dextromoramide is combined with Tizanidine.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tizanidine.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Dezocine is combined with Tizanidine.	Approved
Diazepam	The risk or severity of adverse effects can be increased when Diazepam is combined with Tizanidine.	Approved, Illicit, Vet Approved
Diclofenac	The serum concentration of Tizanidine can be increased when it is combined with Diclofenac.	Approved, Vet Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Diclofenamide.	Approved
Difenoxin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Difenoxin.	Approved, Illicit
Digoxin	Digoxin may increase the bradycardic activities of Tizanidine.	Approved
Dihydrocodeine	The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tizanidine.	Approved, Illicit
Dihydroergotamine	Dihydroergotamine may increase the hypertensive activities of Tizanidine.	Approved
Dihydroetorphine	The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tizanidine.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tizanidine.	Experimental, Illicit
Diltiazem	The risk or severity of adverse effects can be increased when Diltiazem is combined with Tizanidine.	Approved
Dimenhydrinate	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dimenhydrinate.	Approved
Dinutuximab	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dinutuximab.	Approved
Diphenhydramine	The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tizanidine.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tizanidine.	Approved, Illicit
Dipyridamole	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dipyridamole.	Approved
Disopyramide	Tizanidine may increase the QTc-prolonging activities of Disopyramide.	Approved
Disulfiram	The serum concentration of Tizanidine can be increased when it is combined with Disulfiram.	Approved
Dofetilide	Tizanidine may increase the QTc-prolonging activities of Dofetilide.	Approved
Dolasetron	Tizanidine may increase the QTc-prolonging activities of Dolasetron.	Approved
Domperidone	Tizanidine may increase the QTc-prolonging activities of Domperidone.	Approved, Investigational, Vet Approved
Donepezil	Tizanidine may increase the bradycardic activities of Donepezil.	Approved
Dosulepin	Dosulepin may decrease the antihypertensive activities of Tizanidine.	Approved
Doxazosin	The risk or severity of adverse effects can be increased when Doxazosin is combined with Tizanidine.	Approved
Doxepin	Doxepin may decrease the antihypertensive activities of Tizanidine.	Approved
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved, Vet Approved
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved, Illicit
Dronedarone	Tizanidine may increase the QTc-prolonging activities of Dronedarone.	Approved
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved, Vet Approved
Drotebanol	The risk or severity of adverse effects can be increased when Drotebanol is combined with Tizanidine.	Experimental, Illicit
Duloxetine	Tizanidine may increase the orthostatic hypotensive activities of Duloxetine.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Tizanidine.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Tizanidine.	Experimental, Illicit
ECGONINE METHYL ESTER	The risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Tizanidine.	Experimental
Efavirenz	The risk or severity of adverse effects can be increased when Efavirenz is combined with Tizanidine.	Approved, Investigational
Efonidipine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Efonidipine.	Approved
Eliglustat	Tizanidine may increase the QTc-prolonging activities of Eliglustat.	Approved
Empagliflozin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Empagliflozin.	Approved
Enalapril	Tizanidine may increase the hypotensive activities of Enalapril.	Approved, Vet Approved
Enalaprilat	Tizanidine may increase the hypotensive activities of Enalaprilat.	Approved
Enflurane	The risk or severity of adverse effects can be increased when Enflurane is combined with Tizanidine.	Approved, Vet Approved
Entacapone	The serum concentration of Tizanidine can be increased when it is combined with Entacapone.	Approved, Investigational
Eplerenone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Eplerenone.	Approved
Epoprostenol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Epoprostenol.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Tizanidine is combined with Eprosartan.	Approved
Ergoloid mesylate	Ergoloid mesylate may increase the hypertensive activities of Tizanidine.	Approved
Ergonovine	Ergonovine may increase the hypertensive activities of Tizanidine.	Approved
Ergotamine	Ergotamine may increase the hypertensive activities of Tizanidine.	Approved
Erythromycin	Tizanidine may increase the QTc-prolonging activities of Erythromycin.	Approved, Vet Approved
Escitalopram	Tizanidine may increase the QTc-prolonging activities of Escitalopram.	Approved, Investigational
Esmirtazapine	Esmirtazapine may decrease the antihypertensive activities of Tizanidine.	Investigational
Esmolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Esmolol.	Approved
Estazolam	The risk or severity of adverse effects can be increased when Estazolam is combined with Tizanidine.	Approved, Illicit
Estradiol	The serum concentration of Tizanidine can be increased when it is combined with Estradiol.	Approved, Investigational, Vet Approved
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Tizanidine.	Approved
Etacrynic acid	The risk or severity of adverse effects can be increased when Tizanidine is combined with Etacrynic acid.	Approved
Ethanol	Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tizanidine.	Approved, Illicit, Withdrawn
Ethosuximide	The risk or severity of adverse effects can be increased when Ethosuximide is combined with Tizanidine.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ethotoin.	Approved
Ethyl carbamate	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tizanidine.	Withdrawn
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tizanidine.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tizanidine.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Etidocaine is combined with Tizanidine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Etifoxine is combined with Tizanidine.	Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Etizolam is combined with Tizanidine.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Etomidate is combined with Tizanidine.	Approved
Etoperidone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Etoperidone.	Approved
Etorphine	The risk or severity of adverse effects can be increased when Etorphine is combined with Tizanidine.	Illicit, Vet Approved
Ezogabine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ezogabine.	Approved
Felbamate	The risk or severity of adverse effects can be increased when Tizanidine is combined with Felbamate.	Approved
Felodipine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Felodipine.	Approved, Investigational
Fencamfamine	The risk or severity of adverse effects can be increased when Fencamfamine is combined with Tizanidine.	Approved, Illicit, Withdrawn
Fenoldopam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Fenoldopam.	Approved
Fentanyl	The risk or severity of adverse effects can be increased when Fentanyl is combined with Tizanidine.	Approved, Illicit, Investigational, Vet Approved
Fexofenadine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Fexofenadine.	Approved
Fimasartan	The risk or severity of adverse effects can be increased when Tizanidine is combined with Fimasartan.	Approved
Fingolimod	Tizanidine may increase the bradycardic activities of Fingolimod.	Approved, Investigational
Flecainide	Tizanidine may increase the QTc-prolonging activities of Flecainide.	Approved, Withdrawn
Flibanserin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Flibanserin.	Approved
Fluconazole	The serum concentration of Tizanidine can be increased when it is combined with Fluconazole.	Approved
Fludiazepam	The risk or severity of adverse effects can be increased when Fludiazepam is combined with Tizanidine.	Approved, Illicit
Flunarizine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tizanidine.	Approved, Illicit
Fluoxetine	The serum concentration of Tizanidine can be increased when it is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	Tizanidine may increase the QTc-prolonging activities of Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of Tizanidine can be increased when it is combined with Fluphenazine.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Flurazepam is combined with Tizanidine.	Approved, Illicit
Fluspirilene	The risk or severity of adverse effects can be increased when Fluspirilene is combined with Tizanidine.	Approved
Flutamide	The serum concentration of Tizanidine can be increased when it is combined with Flutamide.	Approved
Fluticasone Propionate	The risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Tizanidine.	Approved
Fluvastatin	The serum concentration of Tizanidine can be increased when it is combined with Fluvastatin.	Approved
Fluvoxamine	The serum concentration of Tizanidine can be increased when it is combined with Fluvoxamine.	Approved, Investigational
Fosinopril	Tizanidine may increase the hypotensive activities of Fosinopril.	Approved
Fosphenytoin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Fosphenytoin.	Approved
Fospropofol	The risk or severity of adverse effects can be increased when Fospropofol is combined with Tizanidine.	Approved, Illicit
Furosemide	The risk or severity of adverse effects can be increased when Furosemide is combined with Tizanidine.	Approved, Vet Approved
Gabapentin	The risk or severity of adverse effects can be increased when Gabapentin is combined with Tizanidine.	Approved, Investigational
gabapentin enacarbil	The risk or severity of adverse effects can be increased when Tizanidine is combined with gabapentin enacarbil.	Approved
Gadobenic acid	Tizanidine may increase the QTc-prolonging activities of Gadobenic acid.	Approved
Galantamine	Galantamine may increase the bradycardic activities of Tizanidine.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tizanidine.	Approved, Illicit
Gemifloxacin	Tizanidine may increase the QTc-prolonging activities of Gemifloxacin.	Approved, Investigational
Glutethimide	The risk or severity of adverse effects can be increased when Glutethimide is combined with Tizanidine.	Approved, Illicit
Glycerol Phenylbutyrate	The serum concentration of Tizanidine can be increased when it is combined with Glycerol Phenylbutyrate.	Approved
Goserelin	Tizanidine may increase the QTc-prolonging activities of Goserelin.	Approved
Granisetron	Tizanidine may increase the QTc-prolonging activities of Granisetron.	Approved, Investigational
Guanfacine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Halazepam is combined with Tizanidine.	Approved, Illicit, Withdrawn
Haloperidol	Tizanidine may increase the QTc-prolonging activities of Haloperidol.	Approved
Halothane	The risk or severity of adverse effects can be increased when Halothane is combined with Tizanidine.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Heroin is combined with Tizanidine.	Approved, Illicit
Hexobarbital	The risk or severity of adverse effects can be increased when Hexobarbital is combined with Tizanidine.	Approved
Hyaluronidase	Hyaluronidase may increase the vasoconstricting activities of Tizanidine.	Approved, Investigational
Hydralazine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Hydralazine.	Approved
Hydrochlorothiazide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Hydrochlorothiazide.	Approved, Vet Approved
Hydrocodone	Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydroflumethiazide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Hydroflumethiazide.	Approved
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tizanidine.	Approved, Illicit
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved
Ibutilide	Tizanidine may increase the QTc-prolonging activities of Ibutilide.	Approved
Iloperidone	Tizanidine may increase the QTc-prolonging activities of Iloperidone.	Approved
Iloprost	The risk or severity of adverse effects can be increased when Tizanidine is combined with Iloprost.	Approved, Investigational
Imipramine	The serum concentration of Tizanidine can be increased when it is combined with Imipramine.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Indalpine.	Investigational, Withdrawn
Indapamide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Indapamide.	Approved
Indenolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Indenolol.	Withdrawn
Indoramin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Indoramin.	Withdrawn
Interferon Alfa-2b, Recombinant	The serum concentration of Tizanidine can be increased when it is combined with Interferon Alfa-2b, Recombinant.	Approved
Interferon gamma-1b	The serum concentration of Tizanidine can be increased when it is combined with Interferon gamma-1b.	Approved, Investigational
Iobenguane	The therapeutic efficacy of Iobenguane can be decreased when used in combination with Tizanidine.	Approved
Irbesartan	The risk or severity of adverse effects can be increased when Tizanidine is combined with Irbesartan.	Approved, Investigational
Isocarboxazid	The risk or severity of adverse effects can be increased when Tizanidine is combined with Isocarboxazid.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Isoflurane is combined with Tizanidine.	Approved, Vet Approved
Isoniazid	The serum concentration of Tizanidine can be increased when it is combined with Isoniazid.	Approved
Isosorbide Dinitrate	The risk or severity of adverse effects can be increased when Tizanidine is combined with Isosorbide Dinitrate.	Approved
Isosorbide Mononitrate	The risk or severity of adverse effects can be increased when Tizanidine is combined with Isosorbide Mononitrate.	Approved
Isoxsuprine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Isoxsuprine.	Approved, Withdrawn
Isradipine	The risk or severity of adverse effects can be increased when Isradipine is combined with Tizanidine.	Approved
Ivabradine	Tizanidine may increase the bradycardic activities of Ivabradine.	Approved
Ketamine	The risk or severity of adverse effects can be increased when Ketamine is combined with Tizanidine.	Approved, Vet Approved
Ketazolam	The risk or severity of adverse effects can be increased when Ketazolam is combined with Tizanidine.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Ketobemidone is combined with Tizanidine.	Approved
Ketoconazole	The serum concentration of Tizanidine can be increased when it is combined with Ketoconazole.	Approved, Investigational
Labetalol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Labetalol.	Approved
Lacidipine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Lacidipine.	Approved
Lacosamide	Tizanidine may increase the atrioventricular blocking (AV block) activities of Lacosamide.	Approved
Lamotrigine	The risk or severity of adverse effects can be increased when Lamotrigine is combined with Tizanidine.	Approved, Investigational
Lanreotide	Tizanidine may increase the bradycardic activities of Lanreotide.	Approved
Lenvatinib	Tizanidine may increase the QTc-prolonging activities of Lenvatinib.	Approved
Lercanidipine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Lercanidipine.	Approved, Investigational
Leuprolide	Tizanidine may increase the QTc-prolonging activities of Leuprolide.	Approved, Investigational
Levetiracetam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Levetiracetam.	Approved, Investigational
Levobunolol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tizanidine.	Approved
Levocabastine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Levocabastine.	Approved
Levocetirizine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Levocetirizine.	Approved
Levodopa	Tizanidine may increase the orthostatic hypotensive activities of Levodopa.	Approved
Levofloxacin	Tizanidine may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tizanidine.	Approved
Levomilnacipran	Levomilnacipran may increase the tachycardic activities of Tizanidine.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Levorphanol is combined with Tizanidine.	Approved
Levosimendan	The risk or severity of adverse effects can be increased when Tizanidine is combined with Levosimendan.	Approved, Investigational
Lidocaine	The serum concentration of Tizanidine can be increased when it is combined with Lidocaine.	Approved, Vet Approved
Lisinopril	Tizanidine may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Lithium	The risk or severity of adverse effects can be increased when Lithium is combined with Tizanidine.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Lofentanil is combined with Tizanidine.	Illicit
Lofexidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Lofexidine.	Approved, Investigational
Lomefloxacin	The serum concentration of Tizanidine can be increased when it is combined with Lomefloxacin.	Approved
Lopinavir	Tizanidine may increase the QTc-prolonging activities of Lopinavir.	Approved
Loratadine	The risk or severity of adverse effects can be increased when Loratadine is combined with Tizanidine.	Approved
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Tizanidine.	Approved
Losartan	The serum concentration of Tizanidine can be increased when it is combined with Losartan.	Approved
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Tizanidine.	Approved
Lucinactant	Tizanidine may increase the bradycardic activities of Lucinactant.	Approved
Lumefantrine	Tizanidine may increase the QTc-prolonging activities of Lumefantrine.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Tizanidine.	Approved
Magnesium Sulfate	Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved, Vet Approved
Mannitol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Mannitol.	Approved, Investigational
Maprotiline	The risk or severity of adverse effects can be increased when Tizanidine is combined with Maprotiline.	Approved
Mecamylamine	The risk or severity of adverse effects can be increased when Mecamylamine is combined with Tizanidine.	Approved
Meclizine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Meclizine.	Approved
Mefloquine	The therapeutic efficacy of Tizanidine can be decreased when used in combination with Mefloquine.	Approved
Melatonin	The risk or severity of adverse effects can be increased when Melatonin is combined with Tizanidine.	Approved, Nutraceutical, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Melperone is combined with Tizanidine.	Approved
Mepivacaine	The risk or severity of adverse effects can be increased when Mepivacaine is combined with Tizanidine.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Tizanidine.	Approved, Illicit
Mesoridazine	The risk or severity of adverse effects can be increased when Mesoridazine is combined with Tizanidine.	Approved
Mestranol	The serum concentration of Tizanidine can be increased when it is combined with Mestranol.	Approved
Metaxalone	The risk or severity of adverse effects can be increased when Metaxalone is combined with Tizanidine.	Approved
Methadone	Tizanidine may increase the QTc-prolonging activities of Methadone.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Tizanidine.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Methapyrilene is combined with Tizanidine.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Methaqualone is combined with Tizanidine.	Illicit, Withdrawn
Methazolamide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Methazolamide.	Approved
Methimazole	The serum concentration of Tizanidine can be increased when it is combined with Methimazole.	Approved
Methocarbamol	The risk or severity of adverse effects can be increased when Methocarbamol is combined with Tizanidine.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Methohexital is combined with Tizanidine.	Approved
Methotrimeprazine	Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved
Methoxyflurane	The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tizanidine.	Approved, Vet Approved
Methsuximide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Methsuximide.	Approved
Methyclothiazide	The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tizanidine.	Approved
Methyldopa	The risk or severity of adverse effects can be increased when Tizanidine is combined with Methyldopa.	Approved
Methylphenobarbital	The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tizanidine.	Approved
Metipranolol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Metipranolol.	Approved
Metolazone	The risk or severity of adverse effects can be increased when Metolazone is combined with Tizanidine.	Approved
Metoprolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Metoprolol.	Approved, Investigational
Metyrosine	Tizanidine may increase the sedative activities of Metyrosine.	Approved
Mexiletine	The serum concentration of Tizanidine can be increased when it is combined with Mexiletine.	Approved
Mianserin	The therapeutic efficacy of Tizanidine can be decreased when used in combination with Mianserin.	Approved
Midazolam	The risk or severity of adverse effects can be increased when Midazolam is combined with Tizanidine.	Approved, Illicit
Mifepristone	Mifepristone may increase the QTc-prolonging activities of Tizanidine.	Approved, Investigational
Milnacipran	Milnacipran may increase the tachycardic activities of Tizanidine.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved, Investigational
Minoxidil	The risk or severity of adverse effects can be increased when Minoxidil is combined with Tizanidine.	Approved
Mirtazapine	Mirtazapine may decrease the antihypertensive activities of Tizanidine.	Approved
Moclobemide	The serum concentration of Tizanidine can be increased when it is combined with Moclobemide.	Approved
Moexipril	Tizanidine may increase the hypotensive activities of Moexipril.	Approved
Molindone	The risk or severity of adverse effects can be increased when Molindone is combined with Tizanidine.	Approved
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Tizanidine.	Approved, Investigational
Moxifloxacin	Tizanidine may increase the QTc-prolonging activities of Moxifloxacin.	Approved, Investigational
Moxonidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Moxonidine.	Approved
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved, Investigational
Nadolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Nadolol.	Approved
Nalbuphine	The risk or severity of adverse effects can be increased when Nalbuphine is combined with Tizanidine.	Approved
Nebivolol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Nebivolol.	Approved, Investigational
Nefazodone	The serum concentration of Tizanidine can be increased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Tizanidine can be increased when it is combined with Nelfinavir.	Approved
Nesiritide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Nesiritide.	Approved, Investigational
Nevirapine	The serum concentration of Tizanidine can be increased when it is combined with Nevirapine.	Approved
Nicardipine	The risk or severity of adverse effects can be increased when Nicardipine is combined with Tizanidine.	Approved
Nicorandil	Nicorandil may increase the hypotensive activities of Tizanidine.	Approved
Nifedipine	The serum concentration of Tizanidine can be increased when it is combined with Nifedipine.	Approved
Nilotinib	Tizanidine may increase the QTc-prolonging activities of Nilotinib.	Approved, Investigational
Nilvadipine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Nilvadipine.	Approved
Nimodipine	The risk or severity of adverse effects can be increased when Nimodipine is combined with Tizanidine.	Approved
Nisoldipine	The serum concentration of Tizanidine can be increased when it is combined with Nisoldipine.	Approved
Nitrazepam	The risk or severity of adverse effects can be increased when Nitrazepam is combined with Tizanidine.	Approved
Nitrendipine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Nitrendipine.	Approved
Nitric Oxide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Nitric Oxide.	Approved
Nitroglycerin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Nitroglycerin.	Approved, Investigational
Nitroprusside	The risk or severity of adverse effects can be increased when Nitroprusside is combined with Tizanidine.	Approved
Nitrous oxide	The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tizanidine.	Approved, Vet Approved
Norfloxacin	The serum concentration of Tizanidine can be increased when it is combined with Norfloxacin.	Approved
Norflurane	The risk or severity of adverse effects can be increased when Tizanidine is combined with 1,1,1,2 Tetrafluoroethane.	Investigational
Normethadone	The risk or severity of adverse effects can be increased when Normethadone is combined with Tizanidine.	Approved, Illicit
Nortriptyline	Nortriptyline may decrease the antihypertensive activities of Tizanidine.	Approved
Obeticholic acid	The serum concentration of Tizanidine can be increased when it is combined with Obeticholic acid.	Approved
Obinutuzumab	The risk or severity of adverse effects can be increased when Tizanidine is combined with Obinutuzumab.	Approved
Octreotide	Octreotide may increase the bradycardic activities of Tizanidine.	Approved, Investigational
Ofloxacin	Tizanidine may increase the QTc-prolonging activities of Ofloxacin.	Approved
Olanzapine	The serum concentration of Tizanidine can be increased when it is combined with Olanzapine.	Approved, Investigational
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Tizanidine.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Olopatadine.	Approved
Omapatrilat	Tizanidine may increase the hypotensive activities of Omapatrilat.	Investigational
Omeprazole	The serum concentration of Tizanidine can be increased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
Ondansetron	The serum concentration of Tizanidine can be increased when it is combined with Ondansetron.	Approved
Opium	The risk or severity of adverse effects can be increased when Opium is combined with Tizanidine.	Approved, Illicit
Orlistat	The serum concentration of Tizanidine can be decreased when it is combined with Orlistat.	Approved, Investigational
Orphenadrine	Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Osanetant is combined with Tizanidine.	Investigational
Osimertinib	The serum concentration of Tizanidine can be decreased when it is combined with Osimertinib.	Approved
Oxazepam	The risk or severity of adverse effects can be increased when Oxazepam is combined with Tizanidine.	Approved
Oxprenolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tizanidine.	Approved
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Tizanidine.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Oxymorphone is combined with Tizanidine.	Approved, Investigational, Vet Approved
Paclitaxel	The risk or severity of adverse effects can be increased when Tizanidine is combined with Paclitaxel.	Approved, Vet Approved
Paliperidone	Tizanidine may increase the QTc-prolonging activities of Paliperidone.	Approved
Panobinostat	Tizanidine may increase the QTc-prolonging activities of Panobinostat.	Approved, Investigational
Papaverine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Papaverine.	Approved
Paraldehyde	Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved
Paroxetine	The serum concentration of Tizanidine can be increased when it is combined with Paroxetine.	Approved, Investigational
Pasireotide	Tizanidine may increase the bradycardic activities of Pasireotide.	Approved
Pazopanib	Tizanidine may increase the QTc-prolonging activities of Pazopanib.	Approved
Peginterferon alfa-2a	The serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2a.	Approved, Investigational
Peginterferon alfa-2b	The serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2b.	Approved
Penbutolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Penbutolol.	Approved, Investigational
Pentamidine	Tizanidine may increase the QTc-prolonging activities of Pentamidine.	Approved
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Tizanidine.	Approved, Vet Approved
Pentobarbital	The risk or severity of adverse effects can be increased when Pentobarbital is combined with Tizanidine.	Approved, Vet Approved
Pentoxifylline	The serum concentration of Tizanidine can be increased when it is combined with Pentoxifylline.	Approved, Investigational
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved
Perflutren	Tizanidine may increase the QTc-prolonging activities of Perflutren.	Approved
Perindopril	Tizanidine may increase the hypotensive activities of Perindopril.	Approved
Perospirone	The risk or severity of adverse effects can be increased when Perospirone is combined with Tizanidine.	Approved
Perphenazine	The serum concentration of Tizanidine can be increased when it is combined with Perphenazine.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Tizanidine.	Approved
Phenelzine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Phenelzine.	Approved
Phenobarbital	The metabolism of Tizanidine can be increased when combined with Phenobarbital.	Approved
Phenoxybenzamine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Phenoxybenzamine.	Approved
Phentolamine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Phentolamine.	Approved
Phenylbutyric acid	The serum concentration of Tizanidine can be increased when it is combined with Sodium phenylbutyrate.	Approved, Investigational
Phenytoin	The risk or severity of adverse effects can be increased when Phenytoin is combined with Tizanidine.	Approved, Vet Approved
Pimozide	Tizanidine may increase the QTc-prolonging activities of Pimozide.	Approved
Pindolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Pindolol.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Pipamperone is combined with Tizanidine.	Approved
Pipotiazine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Pipotiazine.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Pomalidomide.	Approved
Poractant alfa	Tizanidine may increase the bradycardic activities of Poractant alfa.	Approved
Practolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Practolol.	Approved
Pramipexole	Tizanidine may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Pramocaine is combined with Tizanidine.	Approved
Prazepam	The risk or severity of adverse effects can be increased when Prazepam is combined with Tizanidine.	Approved, Illicit
Prazosin	The risk or severity of adverse effects can be increased when Prazosin is combined with Tizanidine.	Approved
Pregabalin	The risk or severity of adverse effects can be increased when Pregabalin is combined with Tizanidine.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Prilocaine is combined with Tizanidine.	Approved
Primaquine	Tizanidine may increase the QTc-prolonging activities of Primaquine.	Approved
Primidone	The metabolism of Tizanidine can be increased when combined with Primidone.	Approved, Vet Approved
Procainamide	Tizanidine may increase the QTc-prolonging activities of Procainamide.	Approved
Procaine	The risk or severity of adverse effects can be increased when Procaine is combined with Tizanidine.	Approved, Investigational, Vet Approved
Prochlorperazine	The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tizanidine.	Approved, Vet Approved
Promazine	Tizanidine may increase the QTc-prolonging activities of Promazine.	Approved, Vet Approved
Promethazine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Promethazine.	Approved
Propafenone	The serum concentration of Tizanidine can be increased when it is combined with Propafenone.	Approved
Proparacaine	The risk or severity of adverse effects can be increased when Proparacaine is combined with Tizanidine.	Approved, Vet Approved
Propofol	The serum concentration of Tizanidine can be increased when it is combined with Propofol.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Propoxycaine is combined with Tizanidine.	Approved
Propranolol	The serum concentration of Tizanidine can be increased when it is combined with Propranolol.	Approved, Investigational
Protriptyline	Protriptyline may decrease the antihypertensive activities of Tizanidine.	Approved
Quazepam	The risk or severity of adverse effects can be increased when Quazepam is combined with Tizanidine.	Approved, Illicit
Quetiapine	Tizanidine may increase the QTc-prolonging activities of Quetiapine.	Approved
Quinapril	Tizanidine may increase the hypotensive activities of Quinapril.	Approved, Investigational
Quinidine	Tizanidine may increase the QTc-prolonging activities of Quinidine.	Approved
Quinine	Tizanidine may increase the QTc-prolonging activities of Quinine.	Approved
Ramelteon	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ramelteon.	Approved, Investigational
Ramipril	Tizanidine may increase the hypotensive activities of Ramipril.	Approved
Ranitidine	The serum concentration of Tizanidine can be increased when it is combined with Ranitidine.	Approved
Rasagiline	The risk or severity of adverse effects can be increased when Tizanidine is combined with Rasagiline.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Tizanidine.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Remoxipride is combined with Tizanidine.	Approved, Withdrawn
Rescinnamine	Tizanidine may increase the hypotensive activities of Rescinnamine.	Approved
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Tizanidine.	Approved
Rifampicin	The metabolism of Tizanidine can be increased when combined with Rifampicin.	Approved
Riociguat	The risk or severity of adverse effects can be increased when Tizanidine is combined with Riociguat.	Approved
Risperidone	Tizanidine may increase the hypotensive activities of Risperidone.	Approved, Investigational
Rivastigmine	Tizanidine may increase the bradycardic activities of Rivastigmine.	Approved, Investigational
Ropinirole	The serum concentration of Tizanidine can be increased when it is combined with Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tizanidine.	Approved
Rotigotine	Tizanidine may increase the sedative activities of Rotigotine.	Approved
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Tizanidine.	Approved
Ruxolitinib	Ruxolitinib may increase the bradycardic activities of Tizanidine.	Approved
Sacubitril	The risk or severity of adverse effects can be increased when Tizanidine is combined with Sacubitril.	Approved
Saquinavir	Tizanidine may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Scopolamine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Scopolamine.	Approved
Secobarbital	The risk or severity of adverse effects can be increased when Secobarbital is combined with Tizanidine.	Approved, Vet Approved
Selegiline	The serum concentration of Tizanidine can be increased when it is combined with Selegiline.	Approved, Investigational, Vet Approved
Sertindole	The risk or severity of adverse effects can be increased when Sertindole is combined with Tizanidine.	Approved, Withdrawn
Sertraline	The serum concentration of Tizanidine can be increased when it is combined with Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Sevoflurane is combined with Tizanidine.	Approved, Vet Approved
Silodosin	Silodosin may decrease the vasoconstricting activities of Tizanidine.	Approved
Simeprevir	The serum concentration of Tizanidine can be increased when it is combined with Simeprevir.	Approved
Sodium Nitrite	The risk or severity of adverse effects can be increased when Tizanidine is combined with Sodium Nitrite.	Approved
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved
Sotalol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Sotalol.	Approved
Spirapril	Tizanidine may increase the hypotensive activities of Spirapril.	Approved
Spironolactone	Spironolactone may decrease the vasoconstricting activities of Tizanidine.	Approved
Stiripentol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Stiripentol.	Approved
Streptokinase	The risk or severity of adverse effects can be increased when Tizanidine is combined with Streptokinase.	Approved
Sufentanil	Tizanidine may increase the bradycardic activities of Sufentanil.	Approved, Investigational
Sulconazole	The serum concentration of Tizanidine can be increased when it is combined with Sulconazole.	Approved
Sulfisoxazole	Tizanidine may increase the QTc-prolonging activities of Sulfisoxazole.	Approved, Vet Approved
Sulpiride	The risk or severity of adverse effects can be increased when Sulpiride is combined with Tizanidine.	Approved
Suvorexant	Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved
Synthetic Conjugated Estrogens, A	The serum concentration of Tizanidine can be increased when it is combined with Synthetic Conjugated Estrogens, A.	Approved
Tamsulosin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Tamsulosin.	Approved, Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Tizanidine is combined with Tasimelteon.	Approved
Telavancin	Tizanidine may increase the QTc-prolonging activities of Telavancin.	Approved
Telithromycin	Tizanidine may increase the QTc-prolonging activities of Telithromycin.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Tizanidine is combined with Telmisartan.	Approved, Investigational
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Tizanidine.	Approved
Temocapril	Tizanidine may increase the hypotensive activities of Temocapril.	Experimental, Investigational
Tenofovir	The serum concentration of Tizanidine can be increased when it is combined with Tenofovir.	Approved, Investigational
Terazosin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Terazosin.	Approved
Teriflunomide	The serum concentration of Tizanidine can be decreased when it is combined with Teriflunomide.	Approved
Tetrabenazine	Tizanidine may increase the QTc-prolonging activities of Tetrabenazine.	Approved
Tetracaine	The risk or severity of adverse effects can be increased when Tetracaine is combined with Tizanidine.	Approved, Vet Approved
Tetrodotoxin	The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tizanidine.	Investigational
Thalidomide	Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Theophylline	The serum concentration of Tizanidine can be increased when it is combined with Theophylline.	Approved
Thiamylal	The risk or severity of adverse effects can be increased when Thiamylal is combined with Tizanidine.	Approved, Vet Approved
Thiopental	The risk or severity of adverse effects can be increased when Thiopental is combined with Tizanidine.	Approved, Vet Approved
Thioridazine	The serum concentration of Tizanidine can be increased when it is combined with Thioridazine.	Withdrawn
Thiothixene	The risk or severity of adverse effects can be increased when Thiothixene is combined with Tizanidine.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Tiagabine.	Approved
Tianeptine	Tianeptine may decrease the antihypertensive activities of Tizanidine.	Approved
Tiapride	The risk or severity of adverse effects can be increased when Tizanidine is combined with Tiapride.	Approved, Investigational
Ticlopidine	The serum concentration of Tizanidine can be increased when it is combined with Ticlopidine.	Approved
Timolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Timolol.	Approved
Tioconazole	The serum concentration of Tizanidine can be increased when it is combined with Tioconazole.	Approved
Tofacitinib	Tofacitinib may increase the bradycardic activities of Tizanidine.	Approved, Investigational
Tolazoline	The risk or severity of adverse effects can be increased when Tizanidine is combined with Tolazoline.	Approved, Vet Approved
Tolcapone	The risk or severity of adverse effects can be increased when Tolcapone is combined with Tizanidine.	Approved, Withdrawn
Topiramate	The risk or severity of adverse effects can be increased when Topiramate is combined with Tizanidine.	Approved
Torasemide	The risk or severity of adverse effects can be increased when Torasemide is combined with Tizanidine.	Approved
Toremifene	Tizanidine may increase the QTc-prolonging activities of Toremifene.	Approved, Investigational
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Tizanidine.	Approved, Investigational
Trandolapril	Tizanidine may increase the hypotensive activities of Trandolapril.	Approved
Trans-2-Phenylcyclopropylamine	The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tizanidine.	Experimental
Tranylcypromine	The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tizanidine.	Approved
Trazodone	The risk or severity of adverse effects can be increased when Trazodone is combined with Tizanidine.	Approved, Investigational
Tretinoin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Tretinoin.	Approved, Investigational, Nutraceutical
Triamterene	The risk or severity of adverse effects can be increased when Triamterene is combined with Tizanidine.	Approved
Triazolam	The risk or severity of adverse effects can be increased when Triazolam is combined with Tizanidine.	Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tizanidine.	Approved
Triflupromazine	The risk or severity of adverse effects can be increased when Triflupromazine is combined with Tizanidine.	Approved, Vet Approved
Trimazosin	Trimazosin may decrease the vasoconstricting activities of Tizanidine.	Experimental
Trimipramine	Trimipramine may decrease the antihypertensive activities of Tizanidine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Triprolidine is combined with Tizanidine.	Approved
Valaciclovir	The serum concentration of Tizanidine can be increased when it is combined with Valaciclovir.	Approved, Investigational
Valproic Acid	The risk or severity of adverse effects can be increased when Valproic Acid is combined with Tizanidine.	Approved, Investigational
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Tizanidine.	Approved, Investigational
Vandetanib	Tizanidine may increase the QTc-prolonging activities of Vandetanib.	Approved
Vemurafenib	The serum concentration of Tizanidine can be increased when it is combined with Vemurafenib.	Approved
Venlafaxine	Venlafaxine may increase the tachycardic activities of Tizanidine.	Approved
Verapamil	The serum concentration of Tizanidine can be increased when it is combined with Verapamil.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Vigabatrin.	Approved
Vortioxetine	The risk or severity of adverse effects can be increased when Vortioxetine is combined with Tizanidine.	Approved
Zafirlukast	The serum concentration of Tizanidine can be increased when it is combined with Zafirlukast.	Approved, Investigational
Zaleplon	The risk or severity of adverse effects can be increased when Zaleplon is combined with Tizanidine.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ziconotide.	Approved
Zileuton	The serum concentration of Tizanidine can be increased when it is combined with Zileuton.	Approved, Investigational, Withdrawn
Zimelidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Zimelidine.	Withdrawn
Ziprasidone	Tizanidine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Zolpidem	Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Zonisamide.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Zopiclone is combined with Tizanidine.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Zotepine is combined with Tizanidine.	Approved
Zuclopenthixol	Tizanidine may increase the QTc-prolonging activities of Zuclopenthixol.	Approved, Investigational

Food Interactions

Not Available

References

Synthesis Reference

Pavel Hradil, Lubomir Kvapil, Martin Grepl, Jan Novotny, “METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE.” U.S. Patent US20110263863, issued October 27, 2011.

US20110263863

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB60964
KEGG Compound	C07452
PubChem Compound	5487
PubChem Substance	46505373
ChemSpider	5287
BindingDB	50240671
ChEBI	63629
ChEMBL	CHEMBL1079
Therapeutic Targets Database	DAP000234
PharmGKB	PA451701
Drug Product Database	11821
RxList	http://www.rxlist.com/cgi/generic/tizanidine.htm
Drugs.com	http://www.drugs.com/tizanidine.html
Wikipedia	Tizanidine

ATC Codes

M03BX02

AHFS Codes

12:20.00

PDB Entries

Not Available

FDA label

Download (145 KB)

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Other	Malignant Melanoma, Neoplasms	1
1	Completed	Treatment	Healthy Volunteers	2
1	Terminated	Treatment	Spasticity Due to Cerebral Palsy	1
1, 2	Completed	Treatment	Muscle Spasticity	1
2	Completed	Treatment	Spasticity	1
2	Not Yet Recruiting	Treatment	Acute Muscle Pain	1
3	Completed	Treatment	Low Back Pain (LBP)	1
3	Completed	Treatment	Multiple Sclerosis (MS) / Muscle Spasticity / Spinal Cord Injuries (SCI) / Stroke	1
3	Completed	Treatment	Vertebrogenic Radiculopathy L5, S1	1
4	Completed	Treatment	Thyroidectomy	1
4	Completed	Treatment	Unilateral Inguinal Hernia	1
4	Completed	Treatment	Upper Limb Spasticity	1
4	Recruiting	Treatment	Low Back Pain (LBP)	1
Not Available	Enrolling by Invitation	Not Available	Arthritis / Gout / Headaches / Migraines / Muscle Spasms / Radicular syndrome / Synovitis / Tendonitis	1

Pharmacoeconomics

Manufacturers

Acorda therapeutics inc
Actavis elizabeth llc
Actavis totowa llc
Alphapharm party ltd
Apotex inc
Barr laboratories inc
Caraco pharmaceutical laboratories ltd
Corepharma llc
Dr reddys laboratories inc
Ivax pharmaceuticals inc sub teva pharmaceuticals usa
Mylan pharmaceuticals inc
Sandoz inc
Teva pharmaceuticals usa inc

Packagers

Acorda Therapeutics
Aidarex Pharmacuticals LLC
Alphapharm Party Ltd.
Altura Pharmaceuticals Inc.
Amerisource Health Services Corp.
Amneal Pharmaceuticals
Apotex Inc.
A-S Medication Solutions LLC
Bryant Ranch Prepack
Caraco Pharmaceutical Labs
Cardinal Health
Corepharma LLC
Deca Pharmaceuticals LLC
Dispensing Solutions
Diversified Healthcare Services Inc.
Doctor Reddys Laboratories Ltd.
Elan Pharmaceuticals Inc.
Eon Labs
Genpharm LP
H.J. Harkins Co. Inc.
Heartland Repack Services LLC
Innoviant Pharmacy Inc.
Ivax Pharmaceuticals
Keltman Pharmaceuticals Inc.
Lake Erie Medical and Surgical Supply
Major Pharmaceuticals
Murfreesboro Pharmaceutical Nursing Supply
Mylan
Nucare Pharmaceuticals Inc.
Palmetto Pharmaceuticals Inc.
Par Pharmaceuticals
Patheon Inc.
PCA LLC
PD-Rx Pharmaceuticals Inc.
Physicians Total Care Inc.
Preferred Pharmaceuticals Inc.
Prepak Systems Inc.
Rebel Distributors Corp.
Redpharm Drug
Resource Optimization and Innovation LLC
Southwood Pharmaceuticals
St Mary's Medical Park Pharmacy
Stat Rx Usa
Torpharm Inc.
UDL Laboratories
Vangard Labs Inc.

Dosage forms

Form	Route	Strength
Kit
Tablet	Oral	4 mg
Tablet	Oral	2 mg/1
Tablet	Oral	2 mg
Tablet	Oral	4 mg/1
Capsule, gelatin coated	Oral	2 mg/1
Capsule, gelatin coated	Oral	4 mg/1
Capsule, gelatin coated	Oral	6 mg/1
Capsule	Oral	2 mg/1
Capsule	Oral	4 mg/1
Capsule	Oral	6 mg/1

Prices

Unit description	Cost	Unit
Zanaflex 6 mg capsule	4.79USD	capsule
Zanaflex 4 mg capsule	3.2USD	capsule
Zanaflex 2 mg capsule	2.52USD	capsule
Zanaflex 4 mg tablet	2.29USD	tablet
Tizanidine hcl 4 mg tablet	1.49USD	tablet
Zanaflex 2 mg tablet	1.42USD	tablet
Tizanidine hcl 2 mg tablet	1.25USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US6455557	No	2001-11-28	2021-11-28	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
logP	1.4	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.133 mg/mL	ALOGPS
logP	1.6	ALOGPS
logP	2.02	ChemAxon
logS	-3.3	ALOGPS
pKa (Strongest Basic)	7.49	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	5	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	62.2 Å²	ChemAxon
Rotatable Bond Count	1	ChemAxon
Refractivity	64.77 m³·mol^-1	ChemAxon
Polarizability	23.97 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.8592
Caco-2 permeable	+	0.5323
P-glycoprotein substrate	Substrate	0.6545
P-glycoprotein inhibitor I	Non-inhibitor	0.8365
P-glycoprotein inhibitor II	Non-inhibitor	0.7953
Renal organic cation transporter	Inhibitor	0.6577
CYP450 2C9 substrate	Non-substrate	0.7953
CYP450 2D6 substrate	Non-substrate	0.8018
CYP450 3A4 substrate	Non-substrate	0.5795
CYP450 1A2 substrate	Non-inhibitor	0.5248
CYP450 2C9 inhibitor	Non-inhibitor	0.7117
CYP450 2D6 inhibitor	Non-inhibitor	0.7867
CYP450 2C19 inhibitor	Non-inhibitor	0.6353
CYP450 3A4 inhibitor	Non-inhibitor	0.781
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.5
Ames test	Non AMES toxic	0.6538
Carcinogenicity	Non-carcinogens	0.8915
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	2.6573 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.6935
hERG inhibition (predictor II)	Non-inhibitor	0.8907

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available
MS	Mass Spectrum (Electron Ionization)	splash10-0udi-5490000000-5ee0610f321160b63c82	View in MoNA

Taxonomy

Description

This compound belongs to the class of organic compounds known as benzothiadiazoles. These are heterocyclic aromatic compounds containing a benzene ring fused to a thiadiazole ring. Thiadiazole is a five-membered aromatic heterocycle made up of one sulfur atom and two nitrogen atoms.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Benzothiadiazoles

Sub Class

Not Available

Direct Parent

Benzothiadiazoles

Alternative Parents

Substituents

2,1,3-benzothiadiazole
Aryl chloride
Aryl halide
Benzenoid
Azole
Heteroaromatic compound
2-imidazoline
Thiadiazole
Guanidine
Propargyl-type 1,3-dipolar organic compound
Organic 1,3-dipolar compound
Azacycle
Carboximidamide
Organonitrogen compound
Organochloride
Organohalogen compound
Hydrocarbon derivative
Organopnictogen compound
Organic nitrogen compound
Aromatic heteropolycyclic compound

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

imidazoles (CHEBI:63629 )
benzothiadiazole (CHEBI:63629 )

Targets

Details

1. Alpha-2A adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: agonist

General Function:: Thioesterase binding
Specific Function:: Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:: ADRA2A
Uniprot ID:: P08913
Molecular Weight:: 48956.275 Da

References

Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 1996 Nov;279(2):694-702. [PubMed:8930173 ]

Details

2. Alpha-2B adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: agonist

General Function:: Epinephrine binding
Specific Function:: Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:: ADRA2B
Uniprot ID:: P18089
Molecular Weight:: 49565.8 Da

References

Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 1996 Nov;279(2):694-702. [PubMed:8930173 ]

Details

3. Alpha-2C adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: agonist

General Function:: Protein homodimerization activity
Specific Function:: Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:: ADRA2C
Uniprot ID:: P18825
Molecular Weight:: 49521.585 Da

References

Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 1996 Nov;279(2):694-702. [PubMed:8930173 ]

Details

4. Nischarin

Kind: Protein
Organism: Human
Pharmacological action: no
Actions: agonist

General Function:: Phosphatidylinositol binding
Specific Function:: Acts either as the functional imidazoline-1 receptor (I1R) candidate or as a membrane-associated mediator of the I1R signaling. Binds numerous imidazoline ligands that induces initiation of cell-signaling cascades triggering to cell survival, growth and migration. Its activation by the agonist rilmenidine induces an increase in phosphorylation of mitogen-activated protein kinases MAPK1 and MAPK...
Gene Name:: NISCH
Uniprot ID:: Q9Y2I1
Molecular Weight:: 166627.105 Da

References

Rolon PA: Myxoglobulosis of the appendix. Int Surg. 1977 Jun-Jul;62(6-7):355-6. [PubMed:893017 ]

Enzymes

Details

1. Cytochrome P450 1A2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:: CYP1A2
Uniprot ID:: P05177
Molecular Weight:: 58293.76 Da

References

Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423 ]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Shellenberger MK, Groves L, Shah J, Novack GD: A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state. Drug Metab Dispos. 1999 Feb;27(2):201-4. [PubMed:9929503 ]
Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on June 13, 2005 07:24 / Updated on May 19, 2017 16:37

Get DrugBank to go!

Structure for DB00697 (Tizanidine)

Targets

References

References

References

References

Enzymes

References